FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Christian Dittrich

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Anatomy

Tumor Cells, Cultured

Physiology

Cell Divisions

Co-author Network

Publications

TOP 3
Philipp Buchner; Christian Dittrich; Eva Mihola; Azra Sahmanovic; Tanja Steininger; Martin Czejka
Validation of a simple assay for the quantification of the capecitabine metabolites 5'-DFCR and 5'-DFUR for drug monitoring in patients receiving outpatient chemotherapy.
R Königsberg; Georg Pfeiler; Christian Singer; Robert Zeillinger; Andreas Brunner; Nicole Hammerschmid; Tatjana Klement; Christian Dittrich
Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (≥65) patients.
Christian Dittrich; Alexandru Eniu; Bente Frimodt-Moller; Kurt Krejcy; Yushan Liu; Alexey Manikhas; Luna Musib; Ewa Solska; Sergei Tjulandin; Rodica Anghel; István Láng
A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Christian Dittrich (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Philipp Buchner; Christian Dittrich; Eva Mihola; Azra Sahmanovic; Tanja Steininger; Martin Czejka
Validation of a simple assay for the quantification of the capecitabine metabolites 5'-DFCR and 5'-DFUR for drug monitoring in patients receiving outpatient chemotherapy.
Anticancer research 2013;33(3):881-6.
2012: R Königsberg; Georg Pfeiler; Christian Singer; Robert Zeillinger; Andreas Brunner; Nicole Hammerschmid; Tatjana Klement; Christian Dittrich
Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (≥65) patients.
European journal of cancer (Oxford, England : 1990) 2012;48(16):2962-8.
2012: Christian Dittrich; Alexandru Eniu; Bente Frimodt-Moller; Kurt Krejcy; Yushan Liu; Alexey Manikhas; Luna Musib; Ewa Solska; Sergei Tjulandin; Rodica Anghel; István Láng
A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer.
Cancer investigation 2012;30(4):309-16.
2011: Robert Königsberg; Eva Obermayr; Giovanna Bises; Georg Pfeiler; Margit Gneist; Fritz Wrba; Maria de Santis; Robert Zeillinger; Marcus Hudec; Christian Dittrich
Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.
Acta oncologica (Stockholm, Sweden) 2011;50(5):700-10.
2011: Robert Königsberg; Angelika Reiner-Concin; Tanja Steininger; Robert Terkola; Wilfried Büchler; Wolfgang Hulla; Martin Klimpfinger; Christian Dittrich
Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer patients.
Oncology 2011;81(5-6):359-64.
2010: Robert Königsberg; Margit Gneist; Daniela Jahn-Kuch; Georg Pfeiler; Gudrun Hager; Marcus Hudec; Christian Dittrich; Robert Zeillinger
Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods.
Cancer letters 2010;293(1):117-23.
2010: Martina Baur; Christian Dittrich; Katarzyna Elandt; Marco Hassler; Marcus Hudec; Maria Piribauer; Matthias Preusser; Christine Marosi
Frequent MGMT (0(6)-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience.
Radiology and oncology 2010;44(2):113-20.
2008: Anthe S Zandvliet; Jan H M Schellens; Christian Dittrich; Jantien Wanders; Jos H Beijnen; Alwin D R Huitema
Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.
British journal of clinical pharmacology 2008;66(4):485-97.
2008: Martina Baur; Allan T van Oosterom; Véronique Diéras; Michèle Tubiana-Hulin; R Charles Coombes; Thomas Hatschek; Michael Murawsky; May Klink-Alakl; Marcus Hudec; Christian Dittrich
A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer.
Journal of cancer research and clinical oncology 2008;134(2):125-35.
2008: Martina Baur; Anne Drescher; Margit Gneist; Christian Dittrich; Ulrich Jaehde
Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Cancer chemotherapy and pharmacology 2008;61(1):97-104.
2007: Simone Steinbild; Klaus Mross; Annette Frost; Rudolf Morant; Silke Gillessen; Christian Dittrich; Dirk Strumberg; A Hochhaus; Axel R Hanauske; L Edler; Iris Burkholder; Max E Scheulen
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
British journal of cancer 2007;97(11):1480-5.
2007: Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nicholas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Hilary Calvert; Alan V Boddy; Harry Hollema; Regine Féty; Wjf J F Van der Vijgh; Georg Hempel; Etienne Chatelut; Mats Karlsson; Justin Wilkins; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6410-8.
2007: Martina Baur; Margit Gneist; Takashi Owa; Christian Dittrich
Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam (E7070).
Melanoma research 2007;17(5):329-31.
2007: Christian Dittrich; Anthe S Zandvliet; Margit Gneist; Alwin D R Huitema; A A J King; Jantien Wanders
A phase I and pharmacokinetic study of indisulam in combination with carboplatin.
British journal of cancer 2007;96(4):559-66.
2007: Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nikolas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Régine Féty; Ernst de Bruijn; Georg Hempel; Mats Karlsson; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Clinical pharmacokinetics 2007;46(12):1051-68.
2006: Christian Dittrich; Lubos Petruzelka; Pavel Vodvarka; Margit Gneist; Filip Janku; Tamara Kysela; Allen S Melemed; Jane E Latz; Lorinda Simms; Kurt Krejcy
A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(23):7071-8.
2006: Martina Baur; B Fazeny-Doerner; Marcus Hudec; Paul Sevelda; H Salzer; Christian Dittrich
Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study.
Cancer investigation 2006;24(1):22-7.
2005: Ralf-Dieter Hofheinz; Christian Dittrich; Michael A Jakupec; A Drescher; Ulrich Jaehde; Margit Gneist; Nikolai Graf von Keyserlingk; Bernhard K Keppler; Andreas Hochhaus
Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV).
International journal of clinical pharmacology and therapeutics 2005;43(12):590-1.
2005: Stephen Chan; Max E Scheulen; Stephen Johnston; Klaus Mross; Fatima Cardoso; Christian Dittrich; Wolfgang Eiermann; Dagmar Hess; Rudolf Morant; Vladimir Semiglazov; Markus M Borner; Marc Salzberg; Valerijus Ostapenko; Hans-Joachim Illiger; Dirk Behringer; Nathalie Bardy-Bouxin; Joseph Boni; Steven Kong; Maria Cincotta; Laurence Moore
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(23):5314-22.
2005: Charlotte van Kesteren; Anthe S Zandvliet; Mats O Karlsson; Ron A A Mathôt; Cornelis J A Punt; Jean-Pierre Armand; Eric Raymond; Alwin D R Huitema; Christian Dittrich; Herlinde Dumez; Henri Roché; Jean Pierre Droz; Miroslav Ravic; S Murray Yule; Jantien Wanders; Jos H Beijnen; Pierre Fumoleau; Jan H M Schellens
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
Investigational new drugs 2005;23(3):225-34.
2005: Alexander Becherer; Maria De Santis; Georgios Karanikas; Monica Szabó; Carsten Bokemeyer; Bernhard M Dohmen; Jörg Pont; Robert Dudczak; Christian Dittrich; Kurt Kletter
FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.
European journal of radiology 2005;54(2):284-8.
2005: Martina Baur; E Schernhammer; Margit Gneist; Paul Sevelda; Paul Speiser; Marcus Hudec; Christian Dittrich
Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer.
British journal of cancer 2005;92(6):1019-25.
2005: John F Smyth; S Aamdal; A Awada; Christian Dittrich; Francesco Caponigro; Patrick Schöffski; M Gore; T Lesimple; N Djurasinovic; B Baron; Miroslav Ravic; Pierre Fumoleau; Cornelis J A Punt
Phase II study of E7070 in patients with metastatic melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(1):158-61.
2004: Florence Duffaud; Markus M Borner; P Chollet; Jan B Vermorken; J Bloch; Marian Degardin; Frédéric Rolland; Christian Dittrich; B Baron; Denis Lacombe; Pierre Fumoleau
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
European journal of cancer (Oxford, England : 1990) 2004;40(18):2748-52.
2004: Axel R Hanauske; Christian Dittrich; Jorge Otero
Overview of phase I/II pemetrexed studies.
Oncology (Williston Park, N.Y.) 2004;18(13 Suppl 8):18-25.
2004: Maria De Santis; Alexander Becherer; Carsten Bokemeyer; Franz Stoiber; Karin Oechsle; Franz Sellner; Alois Lang; Kurt Kletter; Bernhard M Dohmen; Christian Dittrich; Jörg Pont
2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(6):1034-9.
2003: Martin J van den Bent; W Grisold; D Frappaz; Roger Stupp; J P Desir; T Lesimple; Christian Dittrich; M J A de Jonge; A Brandes; Marc Frenay; A F Carpentier; P Chollet; J Oliveira; B Baron; D Lacombe; M Schuessler; P Fumoleau
European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1732-4.
2003: Christian Dittrich; Herlinde Dumez; Hilary Calvert; Axel R Hanauske; Marije Faber; Jantien Wanders; Murray Yule; Miroslav Ravic; Pierre Fumoleau
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(14):5195-204.
2003: Martina Baur; Reinhard Walter; Axel Gebauer; Dimiter Tscholakoff; Herbert Lochs; Ferdinand Mühlbacher; Karl Turetschek; Reinhard Binder; Marcus Hudec; Alfred Gangl; Peter Ferenci; Christian Dittrich
Chemoembolization with cisplatin, lipiodol and Gelfoam and subsequent systemic chemotherapy with cisplatin and interferon in patients with hepatocellular carcinoma: a non-randomized prospective study.
International journal of oncology 2003;23(3):811-9.
2003: Christian Dittrich; Véronique Dieras; Pierre Kerbrat; Cornelis Punt; Roberto Sorio; Francesco Caponigro; Xavier Paoletti; Christine de Balincourt; Denis Lacombe; Pierre Fumoleau
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.
Investigational new drugs 2003;21(3):347-52.
2003: Christian Dittrich; Paul Sevelda; H Salzer; Andreas Obermair; Paul Speiser; Gerhard Breitenecker; M Schemper; Alexandra Kaider
Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1129-40.
2003: Christian Dittrich; Bruno Coudert; L Paz-Ares; Francesco Caponigro; Marc Salzberg; T Gamucci; X Paoletti; C Hermans; Denis Lacombe; Pierre Fumoleau
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 2003;39(3):330-4.
2002: Charlotte van Kesteren; Ron A A Mathôt; Eric Raymond; Jean-Pierre Armand; Christian Dittrich; Herlinde Dumez; Henri Roché; Jean Pierre Droz; Cornelis J A Punt; Miroslav Ravic; Jantien Wanders; Jos H Beijnen; Pierre Fumoleau; J H M Schellens
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4065-73.
2002: Martina Baur; Heinz-Roland Kienzer; Maria DeSantis; G Postner; Jörg Pont; Marcus Hudec; Christian Dittrich
Effective salvage therapy with carboplatin/mitomycin C in metastatic breast cancer.
Onkologie 2002;25(3):249-54.
2002: Martina Baur; Heinz-Roland Kienzer; Johannes Schweiger; Maria DeSantis; Erich Gerber; Jörg Pont; Marcus Hudec; Annemarie Ulrike Schratter-Sehn; Wolfram Wicke; Christian Dittrich
Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial.
Cancer 2002;94(11):2953-8.
2002: Chris Twelves; Mario Campone; Bruno Coudert; M Van den Bent; M de Jonge; Christian Dittrich; R Rampling; Roberto Sorio; Denis Lacombe; Christine de Balincourt; Pierre Fumoleau
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(5):777-80.
2002: Christian Dittrich; GA Greim; MM Borner; K Weigang-Köhler; H Huisman; A Amelsberg; A Ehret; Jantien Wanders; Axel R Hanauske; Pierre Fumoleau
Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.
European journal of cancer (Oxford, England : 1990) 2002;38(8):1072-80.
2002: Martina Baur; W Hulla; Heinz-Roland Kienzer; M Klimpfinger; Christian Dittrich
[Pericarditis as the initial manifestation of retroperitoneal fibrosis--a case report].
Wiener medizinische Wochenschrift (1946) 2002;152(9-10):230-2.
2002: Francesco Caponigro; Christian Dittrich; J B Sorensen; J H M Schellens; Florence Duffaud; L Paz Ares; Denis Lacombe; Christine de Balincourt; Pierre Fumoleau
Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(1):70-4.
2001: Maria De Santis; Carsten Bokemeyer; Alexander Becherer; Franz Stoiber; Karin Oechsle; Kurt Kletter; Bernhard M Dohmen; Christian Dittrich; Jörg Pont
Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(17):3740-4.
2001: P Berghammer; R Pöhnl; M Baur; Christian Dittrich
Docetaxel extravasation.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2001;9(2):131-4.
2000: Christian Dittrich
Ifosfamide: actual data, new insights, and persisting questions.
Seminars in oncology 2000;27(1 Suppl 1):1-2.
1998: Andreas Obermair; Paul Speiser; M Thoma; Alexandra Kaider; H Salzer; Christian Dittrich; Paul Sevelda
Prediction of toxicity but not of clinical course by determining carboplatin exposure in patients with epithelial ovarian cancer treated with a combination of carboplatin and cisplatin.
International journal of oncology 1998;13(5):1023-30.
1998: Elisabeth Dittrich; Martin Offterdinger; Sonja M Schneider; Christian Dittrich; Heinz Huber
Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells.
British journal of cancer 1998;78(1):79-87.
1997: Sabine Flicker; Sonja M Schneider; Martin Offterdinger; Elisabeth Dittrich; B Fazeny; Rudolf Valenta; Heinz Huber; Christian Dittrich; Thomas W Grunt
Tyrosine kinase signaling pathways control the expression of retinoic acid receptor-alpha in SK-BR-3 breast cancer cells.
Cancer letters 1997;115(1):63-72.
1997: B Fazeny; Martina Baur; M Prohaska; Marcus Hudec; M Kremnitzer; S Meryn; Heinz Huber; Thomas W Grunt; A Tuchmann; Christian Dittrich
Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature.
Journal of cancer research and clinical oncology 1997;123(1):45-52.
1996: Hanna Harant; R de Martin; PJ Andrew; E Foglar; Christian Dittrich; Ivan J D Lindley
Synergistic activation of interleukin-8 gene transcription by all-trans-retinoic acid and tumor necrosis factor-alpha involves the transcription factor NF-kappaB.
The Journal of biological chemistry 1996;271(43):26954-61.
1996: Georg Krupitza; S Grill; Hanna Harant; Wolfgang Hulla; Thomas Szekeres; Heinz Huber; Christian Dittrich
Genes related to growth and invasiveness are repressed by sodium butyrate in ovarian carcinoma cells.
British journal of cancer 1996;73(4):433-8.
1996: B Fazeny; Udo A Zifko; S Meryn; Heinz Huber; Wolfgang Grisold; Christian Dittrich
Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel--a phase II study.
Cancer chemotherapy and pharmacology 1996;39(1-2):150-6.
1995: Thomas W Grunt; Miguel Saceda; Mary Beth Martin; R Lupu; Elisabeth Dittrich; Georg Krupitza; Hanna Harant; Heinz Huber; Christian Dittrich
Bidirectional interactions between the estrogen receptor and the cerbB-2 signaling pathways: heregulin inhibits estrogenic effects in breast cancer cells.
International journal of cancer. Journal international du cancer 1995;63(4):560-7.
1995: Georg Krupitza; R Fritsche; Elisabeth Dittrich; Hanna Harant; Heinz Huber; Thomas W Grunt; Christian Dittrich
Macrophage colony-stimulating factor is expressed by an ovarian carcinoma subline and stimulates the c-myc proto-oncogene.
British journal of cancer 1995;72(1):35-40.
1995: Georg Krupitza; Wolfgang Hulla; Hanna Harant; Elisabeth Dittrich; Enikö Kállay; Heinz Huber; Thomas W Grunt; Christian Dittrich
Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation.
International journal of cancer. Journal international du cancer 1995;61(5):649-57.
1995: Hanna Harant; Ivan J D Lindley; Aumaid Uthman; C Ballaun; Georg Krupitza; Thomas W Grunt; Heinz Huber; Christian Dittrich
Regulation of interleukin-8 gene expression by all-trans retinoic acid.
Biochemical and biophysical research communications 1995;210(3):898-906.
1995: Georg Krupitza; Hanna Harant; Elisabeth Dittrich; Thomas Szekeres; Heinz Huber; Christian Dittrich
Sodium butyrate inhibits c-myc splicing and interferes with signal transduction in ovarian carcinoma cells.
Carcinogenesis 1995;16(5):1199-205.
1995: Robert M Mader; H Zilg; O Schlappack; Guenther G Steger; M Baur; B Greifenberg; U Heberle; Christian Dittrich
Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer.
Cancer chemotherapy and pharmacology 1995;37(1-2):91-6.
1994: Christian Dittrich; Udo A Zifko; B Fazeny; M Fiegl; Wolfgang Grisold; Heinz Huber
Vinorelbine after paclitaxel in breast cancer: cross resistance and cumulative neurotoxicity?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(5):473-4.
1994: Gabriela V Kornek; Markus Raderer; Dieter Depisch; Karin Haider; B Fazeny; Christian Dittrich; Werner Scheithauer
Amonafide as first-line chemotherapy for metastatic breast cancer.
European journal of cancer (Oxford, England : 1990) 1994;30A(3):398-400.
1993: Hanna Harant; I Korschineck; Georg Krupitza; B Fazeny; Christian Dittrich; Thomas W Grunt
Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription.
British journal of cancer 1993;68(3):530-6.
1993: Christian Dittrich; M Baur; N Vavra; Marcus Hudec; B Fazeny; M Barrada; H Salzer; Paul Sevelda
Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(8):697-9.
1993: Thomas W Grunt; H Oeller; C Somay; Elisabeth Dittrich; B Fazeny; C Mannhalter; Christian Dittrich
Modulation of the immunophenotype of ovarian cancer cells by N,N-dimethylformamide and transforming growth factor-beta 1.
Journal of cellular physiology 1993;156(2):358-66.
1993: Christian Dittrich; Paul Sevelda; M Baur; C Marth; Marcus Hudec; N Vavra; Thomas W Grunt; B Fazeny; H Salzer
In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma.
Cancer 1993;71(10):3082-90.
1993: Thomas W Grunt; H Oeller; C Somay; Christian Dittrich
Different propensity for spontaneous differentiation of cell clones isolated from the human ovarian surface epithelial cell line HOC-7.
Differentiation; research in biological diversity 1993;53(1):45-50.
1993: E Küffer; B Fazeny; Paul Speiser; Christine Kurz; N Vavra; Paul Sevelda; Christian Dittrich
[High-dose epirubicin in combination with high-dose ifosfamide plus granulocyte colony stimulating factor in patients with advanced platin-pretreated ovarian cancer. Phase I-II study].
Gynäkologisch-geburtshilfliche Rundschau 1993;33 Suppl 1():296-8.
1992: Thomas W Grunt; C Somay; H Oeller; Elisabeth Dittrich; Christian Dittrich
Comparative analysis of the effects of dimethyl sulfoxide and retinoic acid on the antigenic pattern of human ovarian adenocarcinoma cells.
Journal of cell science 1992;103 ( Pt 2)():501-9.
1992: C Somay; Thomas W Grunt; C Mannhalter; Christian Dittrich
Relationship of myc protein expression to the phenotype and to the growth potential of HOC-7 ovarian cancer cells.
British journal of cancer 1992;66(1):93-8.
1992: Thomas W Grunt; C Somay; Adolf Ellinger; M Pavelka; Elisabeth Dittrich; Christian Dittrich
The differential effects of N,N-dimethylformamide and transforming growth factor-beta 1 on a human ovarian cancer cell line (HOC-7).
Journal of cellular physiology 1992;151(1):13-22.
1992: M Baur; O Schlappack; R Jakesz; Christian Dittrich
[Differential prognosis of patients with breast cancer with pleuritis carcinomatosa and with pulmonary lymphangiosis carcinomatosa].
Wiener klinische Wochenschrift 1992;104(23):714-6.
1992: M Baur; U Hay; Gottfried Novacek; Christian Dittrich; Peter Ferenci
Prevalence of antibodies to hepatitis C virus in patients with hepatocellular carcinoma in Austria.
Archives of virology. Supplementum 1992;4():76-80.
1991: Werner Scheithauer; Christian Dittrich; Gabriela V Kornek; Karin Haider; W Linkesch; H Gisslinger; Dieter Depisch
Phase II study of amonafide in advanced breast cancer.
Breast cancer research and treatment 1991;20(1):63-7.
1991: Thomas W Grunt; C Somay; M Pavelka; Adolf Ellinger; Elisabeth Dittrich; Christian Dittrich
The effects of dimethyl sulfoxide and retinoic acid on the cell growth and the phenotype of ovarian cancer cells.
Journal of cell science 1991;100 ( Pt 3)():657-66.
1991: Thomas W Grunt; Elisabeth Dittrich; C Somay; T Wagner; Christian Dittrich
Separation of clonogenic and differentiated cell phenotypes of ovarian cancer cells (HOC-7) by discontinuous density gradient centrifugation.
Cancer letters 1991;58(1-2):7-16.
1991: Christian Dittrich; Elisabeth Dittrich; Paul Sevelda; Marcus Hudec; H Salzer; Thomas W Grunt; J Eliason
Clonogenic growth in vitro: an independent biologic prognostic factor in ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(3):381-8.
1991: Robert M Mader; Guenther G Steger; K Moser; H Rainer; P Krenmayr; Christian Dittrich
Instability of the anticancer agent etoposide under in vitro culture conditions.
Cancer chemotherapy and pharmacology 1991;27(5):354-60.
1991: M Baur; O Schlappack; L Havelec; Robert M Mader; Christine Marosi; W Scheithauer; Christian Dittrich
[5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma].
Wiener klinische Wochenschrift 1991;103(11):332-9.
1991: Guenther G Steger; Fritz Wrba; Robert M Mader; O Schlappack; Christian Dittrich; H Rainer
Complete remission of metastasised clear cell sarcoma of tendons and aponeuroses.
European journal of cancer (Oxford, England : 1990) 1991;27(3):254-6.
1990: Christian Dittrich
[Euthanasia--limits of therapy in oncology].
Wiener klinische Wochenschrift 1990;102(19):555-6.
1990: Christian Dittrich; Elisabeth Dittrich; Fritz Wrba; Marcus Hudec; Thomas W Grunt; H Salzer; Paul Sevelda; J Eliason
Analysis of factors influencing clonogenic growth in vitro of cells from ovarian carcinoma patients.
Cancer letters 1990;50(3):183-9.
1990: K Karrer; H Salzer; Paul Sevelda; Christian Dittrich
The role of chemotherapy including ifosfamide for ovarian carcinoma. Austrian Collab. Ovarian Cancer Study Group.
Cancer chemotherapy and pharmacology 1990;26 Suppl():S30-2.
1990: N Vavra; M Barrada; R Fitz; Paul Sevelda; M Baur; Christian Dittrich
[Goserelin--a new form of hormone therapy in ovarian cancer].
Gynäkologische Rundschau 1990;30 Suppl 1():61-3.
1990: Christian Dittrich; M Baur; Robert M Mader; O Schlappack; R Dudczak; Thomas Leitha; R Lenzhofer; S Hoffmann; L Vieder; U Heberle
Phase I-II study on weekly administration of pirarubicin in patients with metastatic breast cancer.
American journal of clinical oncology 1990;13 Suppl 1():S29-39.
1989: Guenther G Steger; Robert M Mader; K Derfler; K Moser; Christian Dittrich
Mucin-like cancer-associated antigen (MCA) compared with CA 15-3 in advanced breast cancer.
Klinische Wochenschrift 1989;67(16):813-7.
1988: O K Schlappack; M Baur; G Steger; Christian Dittrich; K Moser
The clinical course of lung metastases from breast cancer.
Klinische Wochenschrift 1988;66(17):790-5.
1988: Guenther G Steger; Christian Dittrich; O Schlappack; Robert M Mader; CHRISTIAN HEROLD; W P Brade; A Keller; K Moser
Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
Journal of cancer research and clinical oncology 1988;114(6):602-4.
1988: Raimund Jakesz; Christian Dittrich; J Funovics; F Hofbauer; H Rainer; G Reiner; M Schemper; R Schiessel; M Starlinger
The effect of adjuvant chemotherapy in gastric carcinoma is dependent on tumor histology: 5-year results of a prospective randomized trial.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1988;110():44-51.
1987: Christian Dittrich; R Jakesz; K Pirich; L Havelec; G Steger; O Schlappack; R Kolb; K Moser
Possible adverse effect of failed adjuvant chemotherapy on the prognosis of women receiving consecutive chemotherapy for recurrent breast cancer.
Journal of cancer research and clinical oncology 1987;113(5):488-94.
1987: Hans-Georg Eichler; B Blöchl-Daum; R Mader; H Rainer; G Steger; Christian Dittrich; K Moser; G Ehninger
Coupling of mitoxantrone to poly(I).poly(C) reduces absorption after intraperitoneal administration.
Chemotherapy 1987;33(3):157-9.
1986: Raimund Jakesz; Christian Dittrich; J Funovics; F Hofbauer; H Rainer; G Reiner; M Schemper; R Schiessel; M Starlinger
[Adjuvant chemotherapy in patients with radical resection of stomach cancer: 5-year results of a prospective randomized study].
Wiener klinische Wochenschrift 1986;98(24):824-30.
1986: Christian Dittrich; C P Schmidbauer; L Havelec; R Lenzhofer; S Breyer; P Porpaczy; K Moser
Assessment of the human tumor cloning assay for urologic malignancies with special emphasis on bladder cancer.
Oncology 1986;43(1):40-5.
1985: Christian Dittrich; R Jakesz; F Wrba; L Havelec; O Haas; J Spona; H Holzner; R Kolb; K Moser
The human tumour cloning assay in the management of breast cancer patients.
British journal of cancer 1985;52(2):197-203.
1984: R Lenzhofer; H Rainer; R Schuster; P Pirker; R Dudczak; Christian Dittrich; K Moser
[Mitoxantrone in the primary treatment of metastasizing breast cancer].
Wiener klinische Wochenschrift 1984;96(9):319-26.
1983: R Lenzhofer; B Schneeweiss; H Rameis; H Eichler; W Graninger; Christian Dittrich; R Dudczak; U Ganzinger; S Gasic; K Moser
[Pharmacokinetics and acute signs of cardiac toxicity during doxorubicin therapy].
Wiener klinische Wochenschrift 1983;95(2):52-5.